Techniques in Vascular & Interventional Radiology
Volume 9, Issue 3 , Pages 113-124 , September 2006

Pre- and Postoperative Clinical Care of Patients Undergoing Interventional Oncology Procedures: A Comprehensive Approach to Preventing and Mitigating Complications

References 

  1. Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734–1739
  2. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54
  3. Lo CM, Ngan H, Tso WK, et al. Randomized control trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171
  4. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut. 2001;48:251–259
  5. Georgiades CS, Eleni Liapi E, Frangakis C, et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol. 2006;17:1619–1624
  6. Kiely JM, Rilling WS, Touzios JG, et al. Chemoembolization in patients at high risk: Results and complications. J Vasc Interv Radiol. 2006;17:47–53
  7. Levy I, Sherman M. Staging of hepatocellular carcinoma: Assessment of the CLIP, Okuda and Child-Pugh Staging Systems in a cohort of 257 patients in Toronto. Gut. 2002;50:881–885
  8. Huang YS, Chiang JH, Wu JC, et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: Predictive value of the monoethylglycinexylidide test. Am J Gastroenterol. 2002;97:1223–1227
  9. Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: A retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862–186823
  10. Ueno S, Tanabe G, Nuruki K, et al. Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: A multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg. 2002;9:469–477
  11. Xia J, Ren Z, Ye S, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol. 2006;59:407–412
  12. Brown DB, Fundakowski CE, Lisker-Melman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2004;15:1209–1218
  13. Varela M, Sala M, Llovet JM, et al. Treatment of hepatocellular carcinoma: Is there an optimal strategy?. Cancer Treat Rev. 2003;29:99–104
  14. Kim P, Prapong W, Sze DY, et al. Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion. Tech Vasc Interv Radiol. 2002;5:127–131
  15. Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma (A 4-year study of 127 French patients). Cancer. 1994;74:16–24
  16. Huang YS, Chiang JH, Wu JC, et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: Predictive value of the monoethylglycinexylidide test. Am J Gastroenterol. 2002;97:1223–1227
  17. Kim W, Clark TW, Baum RA, et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12:965–968
  18. Kim MH, Choi MS, Choi YS, et al. Clinical features of liver abscess developed after radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma. Korean J Hepatol. 2006;12:55–64
  19. Wu JX, Huang JF, Yu ZJ, et al. Factors related to acute upper gastrointestinal bleeding after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Ai Zheng. 2002;21:881–884
  20. Tarazov PG, Polysalov VN, Prozorovskij KV, et al. Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol. 2000;41:156–160
  21. Chung JW, Park JH, Im JG, et al. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1993;187:689–693
  22. Ueno S, Tanabe G, Nuruki K, et al. Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: A multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg. 2002;9:469–477
  23. Roversi R, Ricci S, Gambari PI, et al. Splenic embolization and hepatic chemoembolization: Combined transcatheter treatment of hepatocellular carcinoma in cirrhosis with hypersplenism. Radiol Med (Torino). 1993;85:444–449
  24. Huang JH, Wu PH, Gu YK, et al. Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization. Ai Zheng. 2006;25:1003–1006
  25. Wu JX, Huang JF, Yu ZJ, et al. Factors related to acute upper gastrointestinal bleeding after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Ai Zheng. 2002;21:881–884
  26. Lang BH, Poon RT, Fan ST, et al. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol. 2004;99:2158–2165
  27. Huo TI, Wu JC, Lee PC, et al. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: A prospective study. Liver Int. 2004;24:210–215
  28. Mahnken AH, Gunther RW, Tacke J. Radiofrequency ablation of renal tumors. Eur Radiol. 2004;14:1449–1455Epub 2004 May 19
  29. Brashears JH, Raj GV, Crisci A, et al. Renal cryoablation and radio frequency ablation: An evaluation of worst case scenarios in a porcine model. J Urol. 2005;173:2160–2165
  30. Livraghi T, Lazzaroni S, Meloni F, et al. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2005;92:856–858
  31. Seifert JK, Stewart GJ, Hewitt PM, et al. Interleukin-6 and tumor necrosis factor-alpha levels following hepatic cryotherapy: Association with volume and duration of freezing. World J Surg. 1999;23:1019–1026
  32. Coskun DJ, Gilchrist J, Dupuy D. Lumbosacral radiculopathy following radiofrequency ablation therapy. Muscle Nerve. 2003;28:754–756
  33. Dupas B, Frampas E, Leaute F, et al. Complications of fluoroscopy-, ultrasound-, and CT-guided percutaneous interventional procedures. J Radiol. 2005;86(Pt 2):586–598
  34. Cho CM, Tak WY, Kweon YO, et al. The comparative results of radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma. Korean J Hepatol. 2005;11:59–71
  35. Chen MH, Yang W, Yan K, et al. Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol. 2005;11:6395–640128
  36. Kim YK, Kim CS, Chung GH, et al. Radiofrequency ablation of hepatocellular carcinoma in patients with decompensated cirrhosis: Evaluation of therapeutic efficacy and safety. AJR Am J Roentgenol. 2006;186(Suppl):S261–S268
  37. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(Suppl 1):S194–S205
  38. Salem R, Thurston KG, Carr BI, et al. Yttrium-90 microspheres: Radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13(Suppl):S223–S229
  39. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;15(5):132

PII: S1089-2516(07)00003-0

doi: 10.1053/j.tvir.2007.01.002

Techniques in Vascular & Interventional Radiology
Volume 9, Issue 3 , Pages 113-124 , September 2006

Article Tools

* Image Usage & Resolution